title: [Low-Dose Estramustine Phosphate Monotherapy in Castration-Resistant Prostate Cancer Patients].
abstract: We retrospectively evaluated the efficacy and toxicity of low-dose estramustine phosphate (EMP) monotherapy in patients with castration-resistant prostate cancer (CRPC). We administered EMP at 140 or 280 mg/day to 89 patients between January 2003 and December 2012. None of the patients were receiving concomitant dexamethasone and none had ever been treated with docetaxel. Fifty-three patients (59.6%) experienced a decline in prostate-specific antigen (PSA) levels, including 20 (22.5%) with a decline of more than 50%. The median time to PSA progression was 90 days. PSA-progression-free survival was significantly longer in patients treated with EMP 140 mg compared with patients treated with EMP 280 mg, and there was no significant difference in the incidence of adverse events between the two groups. The most frequent toxicities were nausea and anorexia. Two patients had grade 3 adverse events of pulmonary embolism and liver dysfunction. EMP treatment was discontinued in nine patients (10.1%) because of side effects (nausea and anorexia in 7, liver dysfunction and lacunar infarction in 1). Low-dose EMP monotherapy is well tolerated and can effectively reduce PSA levels.
authors.affiliation: The Department of Urology, Kurashiki Central Hospital.
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Fukui
authors.affiliation: The Department of Urology, Kurashiki Central Hospital.
authors.forename: Kenji
authors.initials: K
authors.lastname: Nakamura
authors.affiliation: The Department of Urology, Kurashiki Central Hospital.
authors.forename: Toru
authors.initials: T
authors.lastname: Sakatani
authors.affiliation: The Department of Urology, Kurashiki Central Hospital.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Atsuta
authors.affiliation: The Department of Urology, Kurashiki Central Hospital.
authors.forename: Takuma
authors.initials: T
authors.lastname: Kato
authors.affiliation: The Department of Urology, Kurashiki Central Hospital.
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Fukumoto
authors.affiliation: The Department of Urology, Kurashiki Central Hospital.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Ito
authors.affiliation: The Department of Urology, Kurashiki Central Hospital.
authors.forename: Koji
authors.initials: K
authors.lastname: Inoue
authors.affiliation: The Department of Urology, Kurashiki Central Hospital.
authors.forename: Akito
authors.initials: A
authors.lastname: Terai
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D018450:Disease Progression; D004961:Estramustine / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D064129:Prostatic Neoplasms, Castration-Resistant / Q000737:chemistry / Q000175:diagnosis / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004961:Estramustine; D017430:Prostate-Specific Antigen